ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Anti-epileptic effect of saikosaponin a by inhibiting ferroptosis via the IL-17/Akt/ERK signaling pathway in the temporal lobe epilepsy model.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Saikosaponin A (SSa), a triterpenoid saponin isolated from Astragalus membranaceus, possesses multiple pharmacological properties, including anticonvulsant, antiepileptic, and anti-inflammatory activities. This study aimed to elucidate the molecular mechanisms by which SSa exerts therapeutic effects in temporal lobe epilepsy (TLE), with a particular focus on the involvement of ferroptosis pathways. In a kainic acid-induced TLE mouse model, electroencephalography (EEG) was used to monitor seizure frequency. Behavioral tests were employed to evaluate cognitive, learning, and memory functions. Additionally, molecular biology techniques were used to investigate the neuroprotective mechanisms of SSa. EEG recordings showed that SSa treatment significantly reduced seizure frequency and severity. Behavioral assessments indicated improvements in cognition, learning, and memory. Histological analysis revealed decreased neuronal death in the hippocampus. Transmission electron microscopy and Golgi-Cox staining demonstrated a marked increase in hippocampal neuron density following SSa treatment. At the cellular level, SSa significantly downregulated the expression of IL-17, phosphorylated Akt (p-Akt), and phosphorylated ERK (p-ERK) in Erastin-induced ferroptotic hippocampal neurons. Notably, the inhibitory effect of SSa on ferroptosis was reversed by IL-17 agonist treatment, suggesting that IL-17 plays a pivotal role in this pathway. In conclusion, SSa alleviates seizures and improves cognitive function in TLE by inhibiting IL-17/Akt/ERK-mediated ferroptosis in hippocampal neurons.
Indexed as
Identifiers
40892103What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.